MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic Therapies

Last month, psychedelic drug developer MindMed scored an FDA breakthrough therapy designation for its LSD-D-tartrate candidate (MM120) in the treatment of generalised anxiety disorder (GAD). The company is preparing to launch a Phase 3 program by year-end. (See FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder….) Notably…

Source